Renalytix plc (RNLXY) stock
RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Financials through Q1 FY2025, quarter ended Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)
Close on Oct 19, 2026Market cap $375.75MP/E –Yield –
Renalytix operating margin
Operating margin is operating income as a percentage of revenue.
Renalytix's operating margin for the twelve months ending Sep 30, 2024 was -1054.9%. For fiscal 2024 it was -1293.5%, against -1240.7% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | -1293.5% | −52.8 |
| FY2023 | Jun 30, 2023 | -1240.7% | +550.0 |
| FY2022 | Jun 30, 2022 | -1790.7% | +349.9 |
| FY2021 | Jun 30, 2021 | -2140.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -784.1% | +1152.5 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -942.8% | +974.9 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -1224.9% | +283.0 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -1218.8% | −409.4 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -1936.6% | −726.9 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -1917.8% | −347.4 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -1507.9% | +282.4 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -809.4% | +821.6 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -1209.7% | +1241.3 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -1570.4% | +512.0 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -1790.3% | −486.4 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -1631.0% | +522.2 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -2451.0% | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -2082.4% | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -1303.9% | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -2153.3% | – |
See a number that looks wrong?